LOCAL ADVANTAGE
GLOBAL OPPORTUNITY
As one of the largest players in the supply chain, Valens is a premium cannabis producer and processor with exciting international growth potential. This is your opportunity to get on board with a truly diversified cannabis company poised to generate continuous, long-term return.
We’ve planted our roots
and we’re here to stay.
Current market.
CURRENT ($)
24-hour Change ($)
24-hour Change (%)
The world is our market.
With the ability to import and export internationally, Valens is set up for every servicing and consumer product opportunity, globally.
Multi-licensed
- Health Canada Dealer’s License (multiple)
- Health Canada ACMPR Cultivation and Processing License
- ISO 17025 Lab accredited – First in Canada for Cannabis
- Thermo Fisher Scientific “Centre of Excellence for Plant-Based Science”
- EU GMP Certification pending
Our Subsidiaries
Valens AgriTech
Premium, proprietary extraction services, and R&D
Supra THC
Globally-recognized testing and analysis
Valens Farms
State-of-the-art, single strain growing capabilities
Industry Support
Valens has received validation from an $80B company, Thermo Fisher Scientific. We’re also the preferred partner of Canopy Growth and other industry leaders.
Investor Presentations
Public Filings
Exceptional Partners.
We work with a number of renowned partners who share our commitment to innovation and supreme quality.
The numbers.
Medical Patients Registered in Canada by 2020
Canadian Medical Market Size
Potential Candian Recreational sales in 2019
European medical and recreational markets expected growth by 2028
The Bottom Line:
With the global legal marijuana market expected to reach 146.4 billion USD by 2025, Valens is in a rare position to capitalize on international opportunities.
The Valens Advantage.
- Full control and transparency from seed to final sale
- Proprietary methods for extraction
- Research and analysis grants
- International capabilities
- Diverse product range
What’s next?
Valens has already made significant strides. By the end of 2018, we will:
- Receive pending GMP certification
- Begin sales of recreational cannabis products and services to Canadian LP’s
- Commence medical sales to international markets
- Launch the Valens brand
Stay up to date.
Sign up to receive the latest investor information and company news.
Scott Young with Investor Relations
at 705-888-2756 or scott@valensgroworks.com.